In contrast with cell therapy approaches based on the transplantation of single cells, the C-Stem™ technology generates 3D neural microtissues containing mature dopaminergic neurons.
Since 2018, preclinical studies demonstrated robust in vivo effects and safety profile, with fast and complete motor function recovery.
Aiming at a first-in-human trial in 2025, TreeFrog is now moving forward with regulatory toxicology studies and is transferring the GMP C-Stem™ platform to a CDMO to manufactue clinical-grade batches.
Neural microtissue containing mature dopaminerguic neurons differentiated
from human induced pluripotent stem cells cultured in 3D using C-Stem™ technology
TreeFrog Therapeutics is advancing a pipeline of hiPSC-derived cell therapies based on the C-Stem technology. Our lead programme is an iPS-based cell therapy for Parkinson’s disease, which will reach IND and Phase I in 2025. We are also developing allogeneic therapies for heart failure with hiPSC-derived cardiac cells, iPS-derived HSC transplants with the EFS, iPS-derived CAR & NK cell therapies for oncology, iPS-derived cell therapies for AMD, as well as exploratory cell therapies for hepatic and pancreatic diseases (acute liver failure and Diabetes Type I)